A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.
Historically, standard treatment of hepatitis C virus (HCV) infection in patients with renal impairment has been limited by low cure rates and poor tolerability. The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of HCV with impressive cure rates >90% and low rates of adverse events. Despite these major advancements, treatment of patients with HCV and advanced chronic kidney disease (CKD) is a major challenge due to the lack of efficacy and safety data in this patient population. The purpose of this review is to summarize the available data for efficacy and safety of the following DAAs in treating HCV patients with advanced Stage 4 and 5 CKD: simeprevir, sofosbuvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir, grazoprevir, elbasvir and daclatasvir.
['Maruyama|Anna|A|', 'Partovi|Nilufar|N|', 'Yoshida|Eric M|EM|', 'Erb|Siegfried R|SR|', 'Azalgara|Vladimir Marquez|VM|', 'Hussaini|Trana|T|']
D000998:Antiviral Agents D016174:Hepacivirus D006526:Hepatitis C D006801:Humans D051436:Renal Insufficiency, Chronic
direct-acting antivirals hepatitis C CKD ESRD chronic renal failure